Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Puma grosses $55mm through its first PIPE; second tranche adds $4.9mm

Executive Summary

Puma Biotechnology Inc. (cancer drug in-licenser) grossed $55mm through the private placement of 14.7mm common shares at $3.75 apiece. Participating institutional investors included Adage Capital Partners (lead), Brookside Capital, H&Q Healthcare Investors, H&Q Life Science Investors, Jennison Associates, Orbimed Private Investments IV, funds managed by T. Rowe Price, and other buyers. Leerink Swann was the placement agent.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Financing
    • Private Investment in Public Equity
    • Private Placement

Related Companies